<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04843033</url>
  </required_header>
  <id_info>
    <org_study_id>SHC024-I-01</org_study_id>
    <nct_id>NCT04843033</nct_id>
  </id_info>
  <brief_title>A Study to Investigate Safety and Tolerability of SH3809 Tablet in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Open-Label Study to Determine Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of SH3809 Tablet in Patients With Advanced Solid Tumors in China</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Sanhome Pharmaceutical, Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Sanhome Pharmaceutical, Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to determine the safety and tolerability of SH3809 in subjects with&#xD;
      advanced solid tumors. The second objective is to evaluate the PK profile and preliminary&#xD;
      efficacy of SH3809 in solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, open-label study to assess the safety,tolerability, pharmacokinetics and&#xD;
      preliminary efficacy of SH3809 tablet, a small molecule inhibitor of SHP2 receptor , in&#xD;
      patients with advanced solid tumors.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities (DLTs)</measure>
    <time_frame>Within the first 28 days of consecutive treatment</time_frame>
    <description>Incidence and nature of DLTs in the dose escalation phase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose(MTD)</measure>
    <time_frame>Within the first 28 days of consecutive treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax</measure>
    <time_frame>4 weeks</time_frame>
    <description>Highest observed plasma concentration of SH3809</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax</measure>
    <time_frame>4 weeks]</time_frame>
    <description>Time of highest observed plasma concentration of SH3809</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T1/2</measure>
    <time_frame>4 weeks</time_frame>
    <description>Elimination half-life of SH3809</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC)</measure>
    <time_frame>4 weeks</time_frame>
    <description>Area under the plasma concentration time curve of SH3809</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate(ORR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Overall response rate of SH3809 per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival(PFS)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rates(DCR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Disease control rates of SH3809 per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response(DOR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>Duration of response of SH3809 per RECIST v1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Daily oral administration of SH3809 tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SH3809 tablet</intervention_name>
    <description>Starting dose 2mg,oral administered once daily. If tolerated subsequent cohorts will test increasing doses (4mg,6mg,8mg,10mg,12mg) of SH3809.</description>
    <arm_group_label>Daily oral administration of SH3809 tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age between 18 and 75 years inclusive;&#xD;
&#xD;
          2. Histologically or cytologically confirmed advanced malignant solid tumors, eligible&#xD;
             patients should be either refractory or intolerant to all available therapies known to&#xD;
             confer a clinical benefit as determined by the investigator, except for primary&#xD;
             hepatic carcinoma;&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1;&#xD;
&#xD;
          4. Life expectancy â‰¥ 3 months;&#xD;
&#xD;
          5. Adequate hematologic, hepatic and renal function;&#xD;
&#xD;
          6. Participant willing to agree to not father a child/become pregnant and comply with&#xD;
             effective contraception criteria;&#xD;
&#xD;
          7. Provision of signed and dated, written informed consent prior to any study-specific&#xD;
             evaluation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous treatment with any SHP2 inhibitors;&#xD;
&#xD;
          2. Spinal cord compression, meningeal metastases or brain metastases unless asymptomatic,&#xD;
             stable and not requiring steroids for at least 2 weeks prior to start of study&#xD;
             treatment;&#xD;
&#xD;
          3. Life-threatening autoimmune disease or autoimmune disorder with long-term steroid&#xD;
             treatment;&#xD;
&#xD;
          4. Active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), human&#xD;
             immunodeficiency virus (HIV) and treponema pallidum (TP);&#xD;
&#xD;
          5. Patients who have impaired cardiac function or clinically significant cardiac&#xD;
             diseases;&#xD;
&#xD;
          6. Active, clinically significant interstitial lung disease or pneumonitis;&#xD;
&#xD;
          7. Females who are pregnant or breastfeeding;&#xD;
&#xD;
          8. Judgment by the investigator that the patient should not participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shun Lu, Ph D</last_name>
    <phone>22200000-3123</phone>
    <email>shunlu_shchest@sina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shun Lu, Ph D</last_name>
      <phone>22200000-3123</phone>
      <email>shunlu_shchest@sina.com</email>
    </contact>
    <investigator>
      <last_name>Shun Lu, Ph D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 9, 2021</study_first_submitted>
  <study_first_submitted_qc>April 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 13, 2021</study_first_posted>
  <last_update_submitted>April 9, 2021</last_update_submitted>
  <last_update_submitted_qc>April 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>advanced solid tum</keyword>
  <keyword>SHP2</keyword>
  <keyword>EGFR</keyword>
  <keyword>NSCLC</keyword>
  <keyword>Colorectal cancer</keyword>
  <keyword>KRAS G12</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

